Trials / Conditions / Stage IIIA Hepatocellular Carcinoma AJCC v8

Stage IIIA Hepatocellular Carcinoma AJCC v8

16 registered clinical trials studyying Stage IIIA Hepatocellular Carcinoma AJCC v8 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Y-90 Versus SBRT for Inoperable HCC NCT05157451	OHSU Knight Cancer Institute	Phase 2
Active Not Recruiting	Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer NCT05194293	Academic and Community Cancer Research United	Phase 2
Terminated	A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz NCT05199285	Academic and Community Cancer Research United	Phase 2
Recruiting	Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, NCT05168163	Academic and Community Cancer Research United	Phase 2
Recruiting	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373	M.D. Anderson Cancer Center	Phase 1
Recruiting	Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904	Emory University	Phase 2
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Recruiting	Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcino NCT04430452	Mary Feng, MD	Phase 2
Active Not Recruiting	Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver NCT04605731	City of Hope Medical Center	Phase 1
Recruiting	Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer NCT04380545	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) NCT03896646	M.D. Anderson Cancer Center	N/A
Completed	An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Adv NCT04022746	M.D. Anderson Cancer Center	N/A
Terminated	BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer NCT03695250	Edward Kim	Phase 1 / Phase 2
Completed	Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cance NCT03439891	Robin Kate Kelley	Phase 2
Completed	Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01176604	M.D. Anderson Cancer Center	N/A